The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) closed the day trading at $27.73 down -8.24% from the previous closing price of $30.22. In other words, the price has decreased by -$8.24 from its previous closing price. On the day, 1.34 million shares were traded.
Ratios:
For a better understanding of KNSA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.54 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 46.27. For the most recent quarter (mrq), Quick Ratio is recorded 3.43 and its Current Ratio is at 3.66. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $40.
On September 13, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $40.
On May 03, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $34.Wells Fargo initiated its Overweight rating on May 03, 2024, with a $34 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 11 ’25 when Quart Barry D sold 12,336 shares for $30.39 per share. The transaction valued at 374,891 led to the insider holds 12,546 shares of the business.
Quart Barry D sold 8,212 shares of KNSA for $249,316 on Jun 10 ’25. The Director now owns 12,546 shares after completing the transaction at $30.36 per share. On Jun 09 ’25, another insider, Quart Barry D, who serves as the Director of the company, sold 6,900 shares for $30.26 each. As a result, the insider received 208,794 and left with 12,546 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.21 while its Price-to-Book (P/B) ratio in mrq is 4.41.
Stock Price History:
Over the past 52 weeks, KNSA has reached a high of $30.69, while it has fallen to a 52-week low of $17.38. The 50-Day Moving Average of the stock is 11.36%, while the 200-Day Moving Average is calculated to be 20.67%.
Shares Statistics:
A total of 42.16M shares are outstanding, with a floating share count of 40.46M. Insiders hold about 44.56% of the company’s shares, while institutions hold 55.50% stake in the company.
Earnings Estimates
The stock of Kiniksa Pharmaceuticals International Plc (KNSA) is currently in the spotlight, with 5.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.22, with high estimates of $0.38 and low estimates of $0.09.
Analysts are recommending an EPS of between $1.42 and $0.62 for the fiscal current year, implying an average EPS of $0.89. EPS for the following year is $1.46, with 5.0 analysts recommending between $2.02 and $1.01.
Revenue Estimates
6 analysts predict $145.22M in revenue for the current quarter. It ranges from a high estimate of $148.21M to a low estimate of $139.58M. As of the current estimate, Kiniksa Pharmaceuticals International Plc’s year-ago sales were $108.63MFor the next quarter, 6 analysts are estimating revenue of $153.83M. There is a high estimate of $156.3M for the next quarter, whereas the lowest estimate is $148.12M.
A total of 6 analysts have provided revenue estimates for KNSA’s current fiscal year. The highest revenue estimate was $604.2M, while the lowest revenue estimate was $596.84M, resulting in an average revenue estimate of $599.62M. In the same quarter a year ago, actual revenue was $423.24MBased on 6 analysts’ estimates, the company’s revenue will be $717.68M in the next fiscal year. The high estimate is $741.71M and the low estimate is $677.5M.
